Navigation Links
Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting
Date:6/18/2010

RIDGEFIELD, Conn., June 18 /PRNewswire/ -- The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women.  The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA).  The FDA will consider the committee's advice as part of its final assessment of the NDA.  

The committee recognized the significant unmet medical need for women with HSDD and the lack of approved treatments for this condition.  Members of the committee advised that additional data are necessary to further support the efficacy and safety profile of flibanserin and recommended that clinical development of the drug continue.

"We are disappointed with the advisory committee's recommendations and will work with the FDA to address questions raised by the advisory committee," said Christopher Corsico, M.D., M.P.H., U.S. medical director, Boehringer Ingelheim Pharmaceuticals, Inc.  "Our ongoing flibanserin clinical trial program demonstrates our continued commitment to women with HSDD."


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
2. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
6. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
7. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
8. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
9. Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim
10. Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
11. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone ... continued commitment to the advancement of the clinical trials segment. Hosted in Miami, ... clinical trial planning and management. , As executive talent specialists in the ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced ... Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the ... the Department of Defense has announced the award of a new Advanced Regenerative ...
(Date:1/18/2017)... PA (PRWEB) , ... January 18, 2017 , ... ... operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency ... engaging panel discussions to examine vital clinical research issues such as trial performance ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
Breaking Biology News(10 mins):